Associated Papers
Subclonal TP53 and KRAS variants combined with poor treatment response identify ultrahigh-risk pediatric patients with T-ALL.
Kempter T et al.
Blood Advances, 2025
39808796 (PubMed )
Supplement: BLOODA_ADV-2024-014209-mmc1.pdf
Germline mutations and developmental mosaicism underlying EGFR-mutant lung cancer.
Burr R et al.
Medrxiv : the Preprint Server for Health Sciences, 2023
37808694 (PubMed )
Supplement: media-2.xlsx › Patient_3
Comprehensive screening of target molecules by next-generation sequencing in patients with malignant solid tumors: guiding entry into phase I clinical trials.
Tanabe Y et al.
Molecular Cancer, 2016
27852271 (PubMed )
Supplement: 12943_2016_553_MOESM3_ESM.xlsx › Sheet1
Select a paper to view details